Congenital Adrenal Hyperplasia (CAH)
What is congenital adrenal hyperplasia (CAH)?
Congenital adrenal hyperplasia (CAH) is a group of inherited genetic disorders that affect the adrenal glands, which are walnut-sized organs above the kidneys that help regulate metabolism, the immune system, blood pressure, and other essential functions. Someone with CAF lacks an enzyme that the adrenal glands use to do these vital jobs, in turn affecting the production of steroid hormones, such as cortisol, testosterone, etc.
What causes congenital adrenal hyperplasia (CAH)?
In 95% of cases, CAH is caused by a lack of the enzyme 21-hydroxylase, but there are also other much rarer enzyme deficiencies that can cause the disease.
CAH is inherited in an autosomal recessive pattern.
What are the symptoms of congenital adrenal hyperplasia (CAH)?
There are two types of CAH: classic CAH and nonclassic CAH. Nonclassic CAH is more mild and common and may not even become evident until childhood or early adulthood. Its symptoms include:
- Irregular or absent menstrual periods in girls
- Severe acne
- Early appearance of public hair
- Rapid growth during childhood, but shorter than average final height
Classic CAH, on the other hand, is more severe and usually detected in infancy. Its symptoms include:
- Lack of cortisol, leading to blood pressure and blood sugar problems, some of which are life-threatening
- Excess male sex hormone, leading to short height, early puberty, abnormal genital development
How is congenital adrenal hyperplasia (CAH) diagnosed?
CAH can be diagnosed prenatally by an amniocentesis test or a chorionic villus sampling test, in which either fluid from the womb or cells from the placenta, respectively, are removed and examined.
After birth, all newborns in the United States are screened for classic CAH. Otherwise, a CAH diagnosis includes the following:
- Physical examination
- Blood and urine tests to measure hormone levels
- Gene testing
- Testing to determine a child’s sex in females with severe ambiguous genitalia
What treatment options are available for congenital adrenal hyperplasia (CAH)?
Although there is currently no cure for CAH, proper treatment and monitoring can allow patients to lead somewhat normal lives. Some treatment options for CAH include:
- Medications to replace deficient hormones, such as corticosteroids to replace cortisol and salt supplements to help retain salt
- Reconstructive surgery for females
Where can I find more information on congenital adrenal hyperplasia (CAH)?
Congenital Adrenal Hyperplasia (CAH) Articles
WHAT THE C@H?!: How This Educational Initiative Supports the Congenital Adrenal Hyperplasia (CAH) Community
For over three decades, Neurocrine Biosciences, Inc. has been working to support individuals with neurological, neuroendocrine and neuropsychiatric disorders through the development of breakthrough treatment
Rare Disease Clinical Trials Are Essential to Help Uncover Potential Patient Solutions: Spotlight on Classic Congenital Adrenal Hyperplasia (CAH)
Acknowledgment: This story is sponsored by Neurocrine Biosciences and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our
Mother of Twins Raises CAH Awareness
When Rachel Matthews birthed her twin boys, Aiden and Gavin, she was ecstatic. But just a day or two after Rachel had returned home with
ICYMI: First Patient Dosed in BBP-631 Trial for CAH
In late January 2022, biopharmaceutical company BridgeBio Pharma, Inc. (“BridgeBio”) shared via news release that the first patient had been dosed in the Phase 1/2
UK MHRA Approves Efmody for CAH
In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates medication, transfusion components, and medical devices, making sure they meet safety and
BBP-631 for CAH Granted Fast Track Designation
According to corporate news shared on Street Insider, biopharmaceutical company BridgeBio Pharma, Inc. (“BridgeBio”) is making ground with its AAV5 gene therapy, BBP-631. Recently, the
11-oxyandrogens Can Be Used as CAH Biomarkers
How can researchers diagnose and study disease progression if typical biomarkers are unavailable or inconclusive? This very issue arose during a study on congenital adrenal
Partnership Will Bring Alkindi for CAH to China
In 2018, China declared congenital adrenal hyperplasia (CAH) to be a rare disease, and it is estimated to affect 1 in every 6084 Chinese